Epidemiological and Clinical Characteristics of 99 Cases of 2019-Novel Coronavirus (2019-nCoV) Pneumonia in Wuhan, China

Chen, Nanshan; Zhou, Min; Dong, Xuan; Qu, Jieming; Gong, Fengyun; Qiu, Yang; Wang, Jingli; Liu, Ying; Yuan, Wei; Xia, Jiaan; Takata, Yasuyuki; Zhang, Xinxin; Zhang, Li

doi:10.2139/ssrn.3523861

Cited by 152 publications

(171 citation statements)

References 0 publications

Supporting

Mentioning

143

Contrasting

Unclassified

Order By: Relevance

“…In another series of 41 cases of hospitalized COVID-19 patients, it has been reported that 5 (12%) patients were diagnosed with acute cardiac injury. [2][3][4][5] Similar to the cardiovascular complications of COVID-19, those of SARS include hypotension, tachycardia, arrhythmias, systolic and diastolic dysfunctions, and sudden death, with tachycardia particularly being the commonest condition persistent in nearly 40% of patients during follow-up. 14…”

Section: Discussionmentioning

confidence: 99%

“…ARDS, as a severe complication, occurred in approximately 19%-29% NCP patients as per previous reports. [2][3][4][5] Thus, we must understand the mechanisms of heart-lung interactions in ARDS patients, particularly the right ventricle function impairments caused by respiratory dysfunction. 26 Logistic regression analysis indicated that NCP severity was a risk factor for AMI in COVID-19 patients.…”

Section: Furthermore Mers-induced Myocarditismentioning

confidence: 99%

“…1 To date, several latest studies have reported the clinical characteristics of hospitalized patients with 2019 novel coronavirus pneumonia (NCP), including signs, symptoms, laboratory test results, imaging features, therapeutic strategies and effects, and multiple organ dysfunction. [2][3][4][5] Notably, acute myocardial injury (AMI), defined as troponin T-hypersensitivity (TNT-HSST) serum levels > 99th percentile upper reference limit (>28 pg/ml) by the American College of Cardiology/American Heart Association Task Force for myocardial infarction and non-myocardial infarction diseases, 6 was detected in approximately 7.2%-12% COVID-19 patients in previous studies. [2][3] Furthermore, both severe acute respiratory syndrome (SARS) and Middle East respiratory syndrome (MERS) have been linked to acute myocarditis, AMI, and rapid-onset heart failure.…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Acute Myocardial Injury of Patients with Coronavirus Disease 2019

Hou

et al. 2020

Preprint

View full text Add to dashboard Cite

Background: Since the outbreak of the Coronavirus Disease 2019 (COVID-19) inChina, respiratory manifestations of the disease have been observed. However, as a fatal comorbidity, acute myocardial injury (AMI) in COVID-19 patients has not been previously investigated in detail. We investigated the clinical characteristics of COVID-19 patients with AMI and determined the risk factors for AMI in them. Methods:We analyzed data from 53 consecutive laboratory-confirmed and hospitalized COVID-19 patients (28 men, 25 women; age, 19-81 years). We collected information on epidemiological and demographic characteristics, clinical features, routine laboratory tests (including cardiac injury biomarkers), echocardiography, electrocardiography, imaging findings, management methods, and clinical outcomes.Results: Cardiac complications were found in 42 of the 53 (79.25%) patients: tachycardia (n=15), electrocardiography abnormities (n=11), diastolic dysfunction (n=20), elevated myocardial enzymes (n=30), and AMI (n=6). All the six AMI patients were aged >60 years; five of them had two or more underlying comorbidities (hypertension, diabetes, cardiovascular diseases, and chronic obstructive pulmonary disease). Novel coronavirus pneumonia (NCP) severity was higher in the AMI patients than in patients with non-definite AMI (p<0.001). All the AMI patients required care in intensive care unit; of them, three died, two remain hospitalized.Multivariate analyses showed that C-reactive protein (CRP) levels, NCP severity, and underlying comorbidities were the risk factors for cardiac abnormalities in COVID-19 patients.All rights reserved. No reuse allowed without permission. author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Furthermore Mers-induced Myocarditismentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Acute Myocardial Injury of Patients with Coronavirus Disease 2019

Hou

et al. 2020

Preprint

View full text Add to dashboard Cite

show abstract

“…The epidemiological background of the virus was thought to stem from a seafood market in Wuhan, China [2]. However, the true epicenter of the initial transfer to humans is still unknown.…”

Section: Introductionmentioning

confidence: 99%

A search for medications to treat COVID-19 via in silico molecular docking models of the SARS-CoV-2 spike glycoprotein and 3CL protease

Hall

2020

Travel Medicine and Infectious Disease

268

218

View full text Add to dashboard Cite

There is an emergent need to search for possible medications. Method: Utilization of the available sequence information, homology modeling, and in slico docking a number of available medications might prove to be effective in inhibiting the SARS-CoV-2 two main drug targets, the spike glycoprotein, and the 3CL protease. Results: Several compounds were determined from the in silico docking models that might prove to be effective inhibitors for SARS-CoV-2. Several antiviral medications: Zanamivir, Indinavir, Saquinavir, and Remdesivir show potential as and 3CL PRO main proteinase inhibitors and as a treatment for COVID-19. Conclusion: Zanamivir, Indinavir, Saquinavir, and Remdesivir are among the exciting hits on the 3CL PRO main proteinase. It is also exciting to uncover that Flavin Adenine Dinucleotide (FAD) Adeflavin, B2 deficiency medicine, and Coenzyme A, a coenzyme, may also be potentially used for the treatment of SARS-CoV-2 infections. The use of these off-label medications may be beneficial in the treatment of the COVID-19.

show abstract

“…19 Death cases were mostly found in the elderly and who already have chronic conditions. 10,20 The confirmed case is defined as either positive of novel coronavirus nucleic acid by real-time fluorescent reverse transcription-polymerase chain reaction detection of respiratory or blood specimens or highly homologous to any known novel coronaviruses through virus gene sequencing of respiratory or blood specimens. Only when body temperature returns to normal for more than 3 days, respiratory symptoms significantly improved and two consecutive tests negative of the nucleic acid of respiratory pathogens, with at least 1 day on sampling interval, people could be allowed to discharge from hospital 9 (Figure 1 as disease prevention and control.…”

mentioning

confidence: 99%